Abstracts tagged "Systemic JIA"

Abstract Number: 2698 • 2019 ACR/ARP Annual Meeting
Reasons for Initiation of Canakinumab of Patients with Systemic Juvenile Idiopathic Arthritis: A Retrospective Medical Chart Review from the United States
Peter Hur¹, Raluca Ionescu-Ittu ², Ameur M. Manceur ², Kathleen G. Lomax ¹, Jordan Cammarota ³, Jipan Xie ⁴, Navneet Sanghera ⁵ and Alexei A. Grom ⁶, ¹Novartis Pharmaceuticals Corporation, East Hanover, NJ, ²Analysis Group, Inc., Montreal, QC, Canada, ³Analysis Group Inc.,, Washington, DC, ⁴Analysis Group, Inc., Los Angeles, CA, ⁵Novartis Pharmaceuticals Corporations, East Hanover, NJ, ⁶Division of Rheumatology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH
Background/Purpose: Systemic juvenile idiopathic arthritis (SJIA) is a rare autoinflammatory disease characterized by fever and arthritis, often accompanied by rash. Canakinumab (CAN) was approved in…
Abstract Number: 780 • 2019 ACR/ARP Annual Meeting
Changes in MiR-17-92 Cluster Expression Link Systemic Juvenile Idiopathic Arthritis, Monocyte-to-Macrophage Differentiation, and Interferon Regulation
Divya Takellapti¹, Xiaoling Niu ², Thuy Do ³ and Grant Schulert ³, ¹Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ²Fudan University, Shanghai, Shanghai, China (People's Republic), ³Division of Rheumatology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH
Background/Purpose: MicroRNAs (miRNAs) are small noncoding RNAs which post-transcriptionally regulate gene expression. The miR-17-92 cluster is well characterized; its overexpression has been found to serve…
Abstract Number: 784 • 2019 ACR/ARP Annual Meeting
Application of Systems Biology-Based In Silico Tools for Optimal Treatment Strategy Identification in Still’s Disease
Cristina Segu-Verges¹, Mireia Coma ¹, Christoph Kessel ², Serge Smeets ³, Dirk Foell ² and Anna Aldea ⁴, ¹Anaxomics, Barcelona, Catalonia, Spain, ²University Hospital Muenster, Muenster, Germany, ³Novartis, Amsterdam, Netherlands, ⁴Novartis, Barcelona, Catalonia, Spain
Background/Purpose: Systemic JIA (sJIA) and Adult Onset Still’s Disease may represent a disease continuum1 of the same autoinflammatory disorder, Still’s Disease. Current challenges in its…
Abstract Number: 813 • 2019 ACR/ARP Annual Meeting
Monocyte and Macrophage Transcriptional Phenotypes in Systemic Juvenile Idiopathic Arthritis Reveal TRIM8 as a Mediator of IFNγ Hyperresponsiveness and Risk for Macrophage Activation Syndrome
Grant Schulert¹, Thuy Do ¹, Sanjeev Dhakal ¹, Ndate Fall ², Mario Medvedovich ³, Sherry Thornton ¹, Nathan salomonis ² and Alexei A. Grom ¹, ¹Division of Rheumatology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ²Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ³University of Cincinnati College of Medicine, Cincinnati, OH
Background/Purpose: Systemic juvenile idiopathic arthritis (SJIA) is a severe and distinct subtype of childhood arthritis. Children with SJIA are at risk for macrophage activation syndrome…
Abstract Number: 915 • 2019 ACR/ARP Annual Meeting
Development and Initial Validation of the Systemic JADAS, a New Composite Disease Activity Score for Systemic Juvenile Idiopathic Arthritis
Jessica Tibaldi¹, Yasser El Miedany ², Pryiankar Pal ³, Soamarat Vilaiyuk ⁴, Raju Khubchandani ⁵, Manuela Pardeo ⁶, Tapas Kumar Sabui ⁷, Sujata Sawhney ⁸, Ricardo Russo ⁹, Flavio Sztajnbok ¹⁰, Rolando Cimaz ¹¹, Francesca Minoia ¹², Motasem O. Alsuweiti ¹³, Ekaterina Alexeeva ¹⁴, Mikhail Kostik ¹⁵, Maria Cristina Maggio ¹⁶, Sulayman Al Mayouf ¹⁷, Claudia Saad ¹⁸, Giovanni Conti ¹⁹, Romina Gallizzi ²⁰, Adele Civino ²¹, Masaki Shimizu ²², Enrico Felici ²³, Angela Pistorio ²⁴, Nicolino Ruperto ²⁵, Alessandro Consolaro ²⁶ and Angelo Ravelli ²⁷, ¹IRCCS Istituto Giannina Gaslini, Università degli Studi di Genova, Genoa, Italy, ²Ain Shams University, Cairo, Egypt, ³Institute of Child Health, Kolkata, India, ⁴Ramathibodi Hospital, Mahidol University, Bangkok, Thailand, ⁵Jaslok Hospital and Research Center, Mumbai, India, ⁶Division of Rheumatology, IRCCS Ospedale Pediatrico Bambino Gesù, Rome, Italy, Rome, Italy, ⁷R G Kar Medical College, Kolkata, Kolkata, India, ⁸Department of pediatric rheumatology, Sir Ganga Ram Hospital, New Delhi, India, New Delhi, India, ⁹Hospital de Pediatría Garrahan, Buenos Aires, Argentina, ¹⁰Universidade do Estado do Rio de Janeiro, Rio de Janeiro, Brazil, ¹¹University Hospital Meyer, Florence, Italy, ¹²Clinica De Marchi Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy, ¹³Queen Rania Children's Hospital, Amman, Jordan, ¹⁴National Medical Research Center of Children`s Health, Moscow, Russia, ¹⁵Saint-Petersburg State Pediatric Medical University, Saint-Petersburg, Russia, ¹⁶Università di Palermo, Dipartimento G. D'Alessandro, Palermo, Italy, ¹⁷King Faisal Specialist Hospital and Research Center, Riyadh, Saudi Arabia, ¹⁸Hospital das Clínicas - Botucatu Medicine University, UNESP, Botucatu, Brazil, ¹⁹AOU G Martino, Messina, Italy, ²⁰Azienda Ospedaliera Universitaria Gaetano Martino, Messina, Messina, Italy, ²¹Pediatric Rheumatology “Vito Fazzi” Hospital, Lecce, Lecce, Italy, ²²Institute of Medical, Pharmaceutical and Health Sciences, Kanazawa, Japan, ²³SS Antonio e Biagio e Cesare Arrigo" Hospital, Alessandria, Italy, ²⁴IRCCS Istituto Giannina Gaslini, Genova, Italy, ²⁵Paediatric Rheumatology International Trials Organisation (PRINTO), Genoa, Italy, ²⁶Università degli Studi di Genova, Dipartimento di Neuroscienze, Riabilitazione, Oftalmologia, Genetica e Scienze Materno-Infantili (DiNOGMI), Genoa, Italy and IRCCS Istituto Giannina Gaslini, Clinica Pediatrica e Reumatologia, Genoa, Italy, Genova, Italy, ²⁷IRCCS Istituto Giannina Gaslini, Università degli Studi di Genova, Genova, Italy
Background/Purpose: The Juvenile Arthritis Disease Activity Score (JADAS) has gained increasing popularity for the measurement of the level of disease activity in patients with juvenile…
Abstract Number: 917 • 2019 ACR/ARP Annual Meeting
Systemic Juvenile Idiopathic Arthritis-Lung Disease: Characterization and Risk Factors
Grant Schulert¹, Shima Yasin ², Brenna Carey ³, Claudia Chalk ³, Thuy Do ¹, Andrew Schapiro ³, Ammar Husami ³, Allen Watts ³, Hermine Brunner ⁴, Jennifer Huggins ³, Elizabeth Mellins ⁵, Esi Morgan ³, Tracy Ting ³, Bruce Trapnell ⁶, Katheryn Wikenheiser-Brokamp ³, Christopher towe ³ and Alexei A. Grom ¹, ¹Division of Rheumatology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ²Division of Rheumatology, Cincinnati Children's Hospital Medical Center, Cincinnati, ³Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ⁴Pediatric Rheumatology Collaborative Study Group (PRCSG), Cincinnati Children’s Hospital Medical Center, Cincinnati, OH, ⁵Stanford University, Palo Alto, ⁶Cincinnati Children's Hospital, Cincinnati
Background/Purpose: Systemic Juvenile Idiopathic Arthritis (SJIA) is associated with a recently recognized albeit poorly defined and characterized lung disease (LD). Our objective is to describe…
Abstract Number: 918 • 2019 ACR/ARP Annual Meeting
Multiplex Serum Analysis Identifies Potential Biomarkers of Systemic Juvenile Idiopathic Arthritis, Macrophage Activation Syndrome, and Associated Pulmonary Alveolar Proteinosis: Evidence for Independently-regulated Hyperinflammatory and Eosinophilic Inflammation
Guangbo Chen ¹, Grant Schulert ², Adriana De Jesus ³, Vivian Saper ⁴, Corinne Schneider ⁵, Bruce Trapnell ⁶, Alexei A. Grom ², Raphaela Goldbach-Mansky ⁷, Elizabeth Mellins ⁴, Purvesh Khatri ⁸ and Scott Canna⁹, ¹Stanford University, Palo Alto, CA, ²Division of Rheumatology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ³NIH/NIAID/TADS, Bethesda, MD, ⁴Stanford University, Palo Alto, ⁵University of Pittsburgh, Pittsburgh, ⁶Cincinnati Children's Hospital, Cincinnati, ⁷Translational Autoinflammatory Diseases Section/NIAID/NIH, Bethesda, MD, ⁸Institute for Immunity, Transplantation and Infection, Stanford University, Palo Alto, ⁹UPMC Children's Hospital of Pittsburgh, Pittsburgh
Background/Purpose: Recent experiences suggest a disturbing epidemic of digital clubbing and insidious, Pulmonary Alveolar Proteinosis (PAP)-like lung disease occurring in patients with Systemic Juvenile Idiopathic…
Abstract Number: 923 • 2018 ACR/ARHP Annual Meeting
Neutrophils from Children with Systemic JIA Exhibit Persistent Proinflammatory Activation Despite Long-Standing Clinically Inactive Disease
Rachel Brown¹, Maggie Henderlight¹, Thuy Do¹, Shima Yasin², Monica DeLay¹, Alexei A. Grom^3,4 and Grant Schulert^2,5, ¹Rheumatology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ²Rheumatology, Divisions of Rheumatology, Cincinnati Children’s Hospital Medical Center, Cincinnati, OH, ³Pediatrics, University of Cincinnati, CINCINNATI, OH, ⁴Rheumatology, Cincinnati Children’s Hospital Medical Center, Cincinnati, OH, ⁵Pediatrics, Department of Pediatrics, University of Cincinnati College of Medicine, Cincinnati, OH
Background/Purpose: Systemic juvenile idiopathic arthritis (SJIA) is a chronic childhood arthropathy with features of autoinflammation. New-onset SJIA is associated with expansion and activation of neutrophils…
Abstract Number: 927 • 2018 ACR/ARHP Annual Meeting
The Reprogramming of Regulatory T Cells to a Th17 Phenotype in Systemic Juvenile Idiopathic Arthritis
Lauren A. Henderson¹, Kacie Hoyt², Jennifer P. Nguyen³, Pui Lee¹, Deepak Rao⁴, Anna Helena Jonsson⁵, Erin Janssen¹, Fatma Dedeoglu¹, Melissa M. Hazen¹, Mindy S. Lo¹, Esra Meidan¹, Mary Beth Son¹, Robert Sundel¹, Matthew L. Stoll⁶, Chad Nusbaum⁷, James A. Lederer⁸, Talal A. Chatila⁹ and Peter A. Nigrovic^1,5, ¹Division of Immunology, Boston Children's Hospital, Harvard Medical School, Boston, MA, ²Division of Immunology, Boston Children's Hospital, Boston, MA, ³Department of Surgery, Brigham and Women's Hospital, Boston, MA, ⁴Human Immunology Center, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, ⁵Division of Rheumatology, Immunology, and Allergy, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, ⁶Pediatric Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ⁷Broad Technology Labs, Broad Institute, Cambridge, MA, ⁸Department of Surgery, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, ⁹Division of Immunology, Boston Children's Hospital, Harvard Medical School, BOSTON, MA
Background/Purpose: Systemic juvenile idiopathic arthritis (sJIA) is characterized by fever and rash at disease onset, which are mediated in part by IL-1β and IL-6. In…
Abstract Number: 1416 • 2018 ACR/ARHP Annual Meeting
Risk Score of Macrophage Activation Syndrome in Patients with Systemic Juvenile Idiopathic Arthritis
Simone Carbogno¹, Denise Pires Marafon², Giulia Marucci³, Manuela Pardeo³, Antonella Insalaco³, Virginia Messia³, Rebecca Nicolai³, Fabrizio De Benedetti⁴ and Claudia Bracaglia³, ¹University of Milan, Milan, Italy, ²Pediatric Unit, Fondazione IRCCS Ca’ Grande Ospedale Maggiore Policlinico, Milan, Italy, ³Division of Rheumatology, IRCCS Ospedale Pediatrico Bambino Gesù, Rome, Italy, ⁴IRCCS Ospedale Pediatrico Bambino Gesù, Roma, Italy
Background/Purpose: Macrophage Activation Syndrome (MAS) is a severe, life-threatening, complication of rheumatic diseases in childhood, particularly of systemic Juvenile Idiopathic Arthritis (sJIA), occurring in approximately…
Abstract Number: 1426 • 2018 ACR/ARHP Annual Meeting
The Utilization of S100 Proteins Testing in Pediatric Rheumatology Patients in a Tertiary Care Institution and Implications for Care
Najla Aljaberi¹, Angela Merritt², Alexei Grom¹, Grant Schulert³, Jennifer L. Huggins⁴, Michael Henrickson⁵ and Hermine I. Brunner¹, ¹Pediatric Rheumatology, Cincinnati Children’s Hospital Medical Center, Cincinnati, OH, ²Pediatric Rheumatology, Division of Rheumatology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ³Rheumatology, Divisions of Rheumatology, Cincinnati Children’s Hospital Medical Center, Cincinnati, OH, ⁴Cincinnati Children’s Hospital Medical Center, Cincinnati, OH, ⁵Cincinnati Children’s Medical Center, Cincinnati, OH
Background/Purpose: S100 proteins are calcium-binding proteins of increasing value as biomarkers in various inflammatory conditions (e.g. autoinflammatory diseases, vasculitides, inflammatory bowel disease). The two highly…
Abstract Number: 1437 • 2018 ACR/ARHP Annual Meeting
Use,Safety and Efficacy of Thalidomide from a Tertiary Level Pediatric Rheumatology Centre in India
Manjari Agarwal¹ and Sujata Sawhney², ¹Institute of Child Health, Attending Consultant, New Delhi, India, ²Paediatric rheumatology, Senior Consultant, New Delhi, India
Background/Purpose: Thalidomide is an effective agent for several pediatric rheumatic diseases: SOJIA, Behcet's disease and recalcitrant skin disease in cSLE to name a few. Systemic…
Abstract Number: 2864 • 2018 ACR/ARHP Annual Meeting
Identification of Optimal Subcutaneous Doses of Tocilizumab in Children with Systemic Juvenile Idiopathic Arthritis
Hermine I. Brunner¹, Nicola Ruperto², Daniel J Lovell¹, Gerd Horneff³, María Luz Gámir-Gámir⁴, Markus Hufnagel⁵, Joy Hsu⁶, Min Bao⁶, Wendy Douglass⁷, Navita L. Mallalieu⁶, Chris Wells⁷, Christopher M. Mela⁸ and Fabrizio De Benedetti⁹, ¹Pediatric Rheumatology Collaborative Study Group (PRCSG), Cincinnati Children’s Hospital Medical Center, Cincinnati, OH, ²Pediatric Rheumatology International Trial Organization (PRINTO), Istituto Giannina Gaslini Pediatria II-Reumatologia, Genoa, Italy, ³Asklepios Clinic Sankt Augustin, and University Hospital of Cologne, Cologne, Germany, ⁴Hospital Ramon y Cajal Unidad de Reumatologia Pediatrica, Madrid, Spain, ⁵Department of Pediatrics and Adolescent Medicine, University Medical Center, Medical Faculty, University of Freiburg, Freiburg, Germany, ⁶Roche Innovation Center, New York, NY, ⁷Roche Products Ltd., Welwyn Garden City, United Kingdom, ⁸Roche Products Ltd, Welwyn Garden City, United Kingdom, ⁹IRCCS Ospedale Pediatrico Bambino Gesù, Roma, Italy
Background/Purpose: Efficacy and safety of intravenous (IV) tocilizumab (TCZ) were shown in patients (pts) with systemic JIA (sJIA) in the phase 3 TENDER study.1 This…
Abstract Number: 2865 • 2018 ACR/ARHP Annual Meeting
Canakinumab, on a Reduced Dose or a Prolonged Dose Interval without Concomitant Corticosteroids and Methotrexate, Maintains Efficacy in Systemic Juvenile Idiopathic Arthritis Patients in Clinical Remission
Pierre Quartier¹, Ekaterina Alexeeva², Carine Wouters³, Inmaculada Calvo⁴, Tilmann Kallinich⁵, Bo Magnusson⁶, Nico Wulffraat⁷, Xiaoling Wei⁸, Alan Slade⁹, Ken Abrams⁹ and Alberto Martini¹⁰, ¹AP-HP, Institut des Maladies Génétiques (IMAGINE), and Université Paris-Descartes, Necker-Enfants Malades Hospital, Paris, France, ²National Medical Research Center of Children's Health and Sechenov First Moscow State Medical University of the Ministry of Health of the Russian Federation, Moscow, Russian Federation, ³Gasthuisberg University Hospital, Leuven, Belgium, ⁴Hospital Universitario La Fe, Valencia, Spain, ⁵Charité Berlin Campus Virchow, Berlin, Germany, ⁶Karolinska University Hospital, Stockholm, Sweden, ⁷University Medical Center Utrecht, Utrecht, Netherlands, ⁸China Novartis Institutes for Biomedical Research Co., Ltd, Beijing, China, ⁹Novartis Pharmaceuticals Corporation, East Hanover, NJ, ¹⁰Universita di Genova Pediatria II, Genova, Italy
Background/Purpose: Treatment with canakinumab (CAN), a selective, human anti-IL-1β monoclonal antibody, has shown sustained therapeutic effect along with corticosteroid dose reduction/discontinuation in patients with systemic…
Abstract Number: 2917 • 2018 ACR/ARHP Annual Meeting
Multiplex Serum Biomarker Analysis before and during Therapy with Canakinumab in Patients with Systemic Juvenile Idiopathic Arthritis
Tanja Hinze¹, Christoph Kessel¹, Claas Hinze¹, Julia Seibert², Hermann Gram² and Dirk Foell³, ¹Department of Pediatric Rheumatology and Immunology, University of Muenster, Muenster, Germany, ²Novartis, Basel, Switzerland, ³Pediatric Rheumatology and Immunology, University of Muenster, Muenster, Germany
Background/Purpose: Canakinumab (CAN), a monoclonal anti-interleukin (IL)-1β antibody, is approved for the treatment of systemic juvenile idiopathic arthritis (SJIA). CAN-treated patients with SJIA showed a…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].